NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other markets where natural-killer ("NK”) cell therapy is already legal. NKGen proposal included up to $18 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback